Education
About Us
Working with TipRanks
Follow Us
Pfizer (PFE)
NYSE:PFE
PFE Analyst Ratings
Hold
4 Buy
12 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PFE Stock 12 Month Forecast
Average Price Target
$28.50
▲(14.97%Upside)
| Highest Price Target$33.00 | Average Price Target$28.50 | Lowest Price Target$24.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$28
Hold
12.95%
Upside
Reiterated
07/23/25
Pfizer's stock score is driven by strong financial performance and a robust R&D pipeline, which are counterbalanced by recent revenue declines and global trade uncertainties. The valuation is appealing due to a high dividend yield, while technical indicators suggest modest positive momentum. Overall, Pfizer is positioned for potential growth despite some challenges.
Bernstein
$30
Hold
21.02%
Upside
Reiterated
07/27/25
Bank of America Securities
$27
Hold
8.91%
Upside
Reiterated
07/25/25
Goldman Sachs
$27
Hold
8.91%
Upside
Reiterated
07/25/25
Pfizer's Uncertain Growth Prospects and Revenue Stability Prompt Hold RatingWe highlight the following items of note: FX topline tailwind: Consistent with US pharma peers and the broader S&P500, n we expect PFE to benefit from the broad-based weakening of the dollar vs. other marjor currencies where we estimate to be a ~$190mn tailwind for 2Q25. OpEx: For the quarter, we estimate in-line R&D expenses and slightly lower SG&A n expenses. For FY25, we model to be ~ 2-3% below consensus, where our estimates of $10.9bn and $13.5bn trends towards the lower end of company guided range of $10.7- $11 .7bn and $13.3- $14.3bn range, respectively, per the company’s continued momentum and management recent commentary on cost control. Acquired IPR&D: While we do not include an IPR&D charge for 2Q25, we do n anticipate inclusion of $1 .25bn IPR&D in 3Q25 (although not yet reflected in model), per company expectation of 3SBio transaction closing.
Morgan Stanley
$32
Hold
29.08%
Upside
Reiterated
07/22/25
Wells Fargo
$28
Hold
12.95%
Upside
Reiterated
07/08/25
J.P. Morgan
$30
Hold
21.02%
Upside
Reiterated
07/08/25
Guggenheim
$33
Buy
33.12%
Upside
Reiterated
06/17/25
UBS
$25
Hold
0.85%
Upside
Reiterated
06/12/25
BMO Capital
$30
Buy
21.02%
Upside
Reiterated
06/12/25
Cantor Fitzgerald
$24
Hold
-3.19%
Downside
Reiterated
06/10/25
Jefferies
$33
Buy
33.12%
Upside
Reiterated
06/04/25
Leerink Partners
―
Hold
―
Reiterated
06/02/25
DBS
$30
Buy
21.02%
Upside
Reiterated
05/30/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$28
Hold
12.95%
Upside
Reiterated
07/23/25
Pfizer's stock score is driven by strong financial performance and a robust R&D pipeline, which are counterbalanced by recent revenue declines and global trade uncertainties. The valuation is appealing due to a high dividend yield, while technical indicators suggest modest positive momentum. Overall, Pfizer is positioned for potential growth despite some challenges.
Bernstein
$30
Hold
21.02%
Upside
Reiterated
07/27/25
Bank of America Securities
$27
Hold
8.91%
Upside
Reiterated
07/25/25
Goldman Sachs
$27
Hold
8.91%
Upside
Reiterated
07/25/25
Pfizer's Uncertain Growth Prospects and Revenue Stability Prompt Hold RatingWe highlight the following items of note: FX topline tailwind: Consistent with US pharma peers and the broader S&P500, n we expect PFE to benefit from the broad-based weakening of the dollar vs. other marjor currencies where we estimate to be a ~$190mn tailwind for 2Q25. OpEx: For the quarter, we estimate in-line R&D expenses and slightly lower SG&A n expenses. For FY25, we model to be ~ 2-3% below consensus, where our estimates of $10.9bn and $13.5bn trends towards the lower end of company guided range of $10.7- $11 .7bn and $13.3- $14.3bn range, respectively, per the company’s continued momentum and management recent commentary on cost control. Acquired IPR&D: While we do not include an IPR&D charge for 2Q25, we do n anticipate inclusion of $1 .25bn IPR&D in 3Q25 (although not yet reflected in model), per company expectation of 3SBio transaction closing.
Morgan Stanley
$32
Hold
29.08%
Upside
Reiterated
07/22/25
Wells Fargo
$28
Hold
12.95%
Upside
Reiterated
07/08/25
J.P. Morgan
$30
Hold
21.02%
Upside
Reiterated
07/08/25
Guggenheim
$33
Buy
33.12%
Upside
Reiterated
06/17/25
UBS
$25
Hold
0.85%
Upside
Reiterated
06/12/25
BMO Capital
$30
Buy
21.02%
Upside
Reiterated
06/12/25
Cantor Fitzgerald
$24
Hold
-3.19%
Downside
Reiterated
06/10/25
Jefferies
$33
Buy
33.12%
Upside
Reiterated
06/04/25
Leerink Partners
―
Hold
―
Reiterated
06/02/25
DBS
$30
Buy
21.02%
Upside
Reiterated
05/30/25
Best Analysts Covering Pfizer
1 Month
xxx
Success Rate
19/35 ratings generated profit
Average Return
+0.93%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 54.29% of your transactions generating a profit, with an average return of +0.93% per trade.
3 Months
xxx
Success Rate
24/35 ratings generated profit
Average Return
+2.71%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 68.57% of your transactions generating a profit, with an average return of +2.71% per trade.
1 Year
Success Rate
26/35 ratings generated profit
Average Return
+5.17%
reiterated a buy rating last month
Copying Vamil Divan's trades and holding each position for 1 Year would result in 74.29% of your transactions generating a profit, with an average return of +5.17% per trade.
2 Years
xxx
Success Rate
26/35 ratings generated profit
Average Return
+7.85%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 74.29% of your transactions generating a profit, with an average return of +7.85% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PFE Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
0
2
2
2
0
Buy
13
14
12
15
10
Hold
26
44
45
55
37
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
39
60
59
72
47
Each month's total comprises the sum of three months' worth of ratings.
PFE Financial Forecast
PFE Stock Forecast FAQ
What is PFE’s average 12-month price target, according to analysts?
Based on analyst ratings, Pfizer’s 12-month average price target is 28.50.
What is PFE’s upside potential, based on the analysts’ average price target?
Pfizer has 14.97% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PFE a Buy, Sell or Hold?
Pfizer has a consensus rating of Hold which is based on 4 buy ratings, 12 hold ratings and 0 sell ratings.
What is Pfizer’s price target?
The average price target for Pfizer is 28.50. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $33.00 ,the lowest forecast is $24.00. The average price target represents 14.97% Increase from the current price of $24.79.
The highest analyst price target is $33.00 ,the lowest forecast is $24.00. The average price target represents 14.97% Increase from the current price of $24.79.
What do analysts say about Pfizer?
Pfizer’s analyst rating consensus is a Hold. This is based on the ratings of 16 Wall Streets Analysts.
How can I buy shares of PFE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.